FDA investigators found "significant objectionable conditions" during an inspection of a Genzyme plant that makes expensive biotechnology drugs, according to a copy of an agency warning letter.
WSJ.com: What's News US, Wall Street Journal
Tue, 03/10/2009 - 8:31am
FDA investigators found "significant objectionable conditions" during an inspection of a Genzyme plant that makes expensive biotechnology drugs, according to a copy of an agency warning letter.